Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

被引：1
|
作者：
Mehta, Pallavi [1 ]
Yadav, Neha [1 ]
Bhaarat, Mohan [2 ]
Mirgh, Sumeet Prakash [3 ]
Khushoo, Vishvdeep [3 ]
Thekuddan, Shinto Francis [1 ]
Agrawal, Narendra [3 ]
Ahmed, Rayaz [4 ]
Bhurani, Dinesh [3 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, Dept Hematooncol, New Delhi, India
[2] Rajiv Gandhi Canc Inst, New Delhi, India
[3] Rajiv Gandhi Canc Inst & Res Ctr, Dept Hematooncol & BMT, New Delhi, India
[4] Rajiv Gandhi Canc Inst & Res Inst, New Delhi, India
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131674
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5572
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China
    Du, Juan
    Fang, Baijun
    Li, Jian
    Jin, Jie
    Wang, Shunqing
    Zou, Dehui
    Cai, Zhen
    Wang, Hongxiang
    Hu, Jianda
    Li, Wei
    Fu, Chengcheng
    Shao, Zonghong
    Xia, Zhongjun
    Liu, Peng
    Niu, Ting
    Tang, En-Tzu
    Kimball, Amy S.
    Hou, Jian
    Chen, Wenming
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 422 - 429
  • [22] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew J.
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Bianchi, Giada
    O'Donnell, Elizabeth
    Branagan, Andrew R.
    Harrington, Cynthia C.
    Agyemang, Emerentia A.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette A.
    Bernstein, Zachary S.
    Lyons, Rebecca T.
    Riadi, Manal
    Rowell, Sean M.
    Mcvey, Cailin
    Goguen, Amy C.
    Horick, Nora K.
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study
    Bringhen, Sara
    Oliva, Stefania
    Liberati, Anna Marina
    Belotti, Angelo
    Larocca, Alessandra
    Bonello, Francesca
    Gaidano, Gianluca
    Bertazzoni, Paola
    Esma, Fabrizio
    Stocchi, Raffaella
    Malfitano, Alessandra
    Ribolla, Rossella
    Di Sano, Chiara
    Aschero, Simona
    Patriarca, Francesca
    De Paoli, Lorenzo
    Cafro, Anna Maria
    Sonneveld, Pieter
    Palumbo, Antonio
    Boccadoro, Mario
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E59 - E59
  • [24] Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
    Matsue, Kosei
    Iwasaki, Hiromi
    Chou, Takaaki
    Tobinai, Kensei
    Sunami, Kazutaka
    Ogawa, Yoshiaki
    Kurihara, Mari
    Midorikawa, Shuichi
    Zaki, Mohamed
    Doerr, Thomas
    Iida, Shinsuke
    CANCER SCIENCE, 2015, 106 (11): : 1561 - 1567
  • [25] Pomalidomide, Cyclophosphamide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Retrospective Single Center Experience
    Garderet, Laurent
    Polge, Emmanuelle
    Gueye, Mor Seny
    Kellil, Chaima
    Ova, Jeanny Guelongo Okouango
    Beohou, Eric
    Labopin, Myriam
    Mohty, Mohamad
    BLOOD, 2015, 126 (23)
  • [26] Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients
    Silvennoinen, Raija Helena
    Nahi, Hareth
    Anttila, Pekka
    Koskenvesa, Perttu
    Lievonen, Juha
    Marttila, Anu
    Varmavuo, Ville
    Sikio, Anu
    Nurmi, Marita
    Saily, Marjaana
    Partanen, Anu
    Sankelo, Marja
    Luoma, Sini
    Mantymaa, Pentti
    Ilveskero, Sorella
    Eshoj, Henrik Rode
    Nielsen, Lene Kongsgaard
    Jantunen, Esa
    Heckman, Caroline A.
    BLOOD, 2020, 136
  • [27] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    BLOOD, 2017, 130 (08) : 974 - 981
  • [28] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
    Paludo, Jonas
    Mikhael, Joseph R.
    LaPlant, Betsy R.
    Halvorson, Alese E.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    Stewart, A. Keith
    Reeder, Craig B.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    BLOOD, 2017, 130 (10) : 1198 - 1204
  • [29] An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma
    Piggin, Anna
    Prince, H. Miles
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (05) : 419 - 427
  • [30] AN INDIRECT COMPARISON OF ELOTUZUMAB, CARFILZOMIB, AND DARATUMUMAB WHEN GIVEN IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Potluri, R.
    Chen, C.
    Ranjan, S.
    Kumar, A.
    Bhandari, H.
    Davis, C.
    VALUE IN HEALTH, 2019, 22 : S104 - S104
12345